Study Group: Freestyle Navigator, Guardian RT, and Dexcom Continuous Glucose Monitoring System Prescribers (US)(?)
Council Members in this Study Group: 16
Request a survey with this Study Group
Leading Experts in this Study Group
Michael Dempsey
Medical Director
Johns Hopkins Diabetes Center at Suburban Hospital
Michael Dempsey, MD, is a Private Practitioner in Rockville, Maryland. He is the Medical Director of the Johns Hopkins Diabetes Center at Suburban Hospital, where he is also the Medical Director of Diabetes Education and Endocrine Subsection Chair. He is the Vice-President of the Mid-Atlantic chapter...
Director of General Internal Medicine
Saint Louis University
George Griffing, MD, is Director of General Internal Medicine at St. Louis University. Dr. Griffing’s clinical expertise includes the diagnosis and treatment of diabetes. His research interests include the clinical investigation of inhaled insulin, nasal insulin and pramlintide. Dr. Griffing is a...
Professor of Medicine and Pediatrics
University of Colorado School of Medicine
Satish K. Garg is Professor of Medicine and Pediatrics at the Young Adult Clinic of the Barbara Davis Center for Diabetes of the University Of Colorado School Of Medicine in Denver, Colorado. His research interests include the early detection and treatment of renal and retinal complications of type1...
Assistant Professor of Medicine and Pediatrics
Rush University Medical Center
Richard Levy, MD, is an Assistant Professor of Medicine and Pediatrics at Rush University Medical Center, and is a privately practicing adult and pediatric endocrinologist and diabetologist in Illinois. Dr. Levy has conducted research on diabetes and lipid abnormalities and is currently participating...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
The recent finding that Byetta therapy decreased mortality in the ACCORD study needs to be replicated in studies designed to address that point. Even if it is replicated and statistically significant, it probably will not be true for the widely anticipated once weekly extended formulation...
Should bisphosphonates be stopped in patients who have been taking them for many years? Should they be used at all?
As exciting as the DURATION I study results have been, Roche's GLP-1 agonist is also looking good in earlier phase trials, and there are MANY competitors in this GLP-1 realm, as well as the gliptins (oral, with similar efficacy on glucose and A1c but without the dramatic weight loss), chomping at the...
This compound may have additiional benefit in type 2 diabetic patients, especially those with the cardiometabolic syndrome.
The recent findings regarding pioglitazone in a large, randomized, intravascular cardiac ultrasound study finally begin to show some indication of the expected efficacy for which many physicians chose to use the drug, i.e., to decrease cardiovascular disease or its progression. From...
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Managed Care Health Insurer, For-Profit
- Private/For-Profit Healthcare Research Entity
- Research Foundation
Most Common Job Types:
- Physician - Attending Physician
- Physician - Division Head
- Physician - Director
- Director
- Owner
- President
- Chief Medical Officer
- Dietitian
- Medical Director
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms